Our Story
The 2024 U.S. Presidential candidates disagree on almost everything. When they talk about the opioid epidemic, they often say the same thing.
Resilient Lifescience faces unique risks in a complex market, here's how we mitigate them
Not enough Americans receive treatment for OUD. Creative outreach efforts like the Bupe Bus can help close the gap.
NIH Grant Awarded and Prototypes Near Completion
Overdose deaths are falling. What's causing this encouraging trend and will it continue?
In May, the Resilient Team kicked off our NSF-sponsored research by developing our naloxone formulation for testing.
Technical Progress, Team Growth, and Federal Funding
We enrolled 30 participants in a calibration study to train our sensor for the accurate monitoring of heart rate, respiratory rate, and oxygen saturation.
Charlie describes recent firmware development work to optimize the power consumption for our device.
Q3 was filled with grant writing, prototype development, and setting up our first large human subject research study.
More engineering progress
The Resilient team moved offices and received some great publicity in June
I moved from Austin to Pittsburgh because Pittsburgh’s a great city to work in
Charlie responds to the Pennsylvania State Senate's decision to ban safe consumption facilities in the state
Engineering progress and an update on our product development Roadmap
In Spring 2023, the FDA approved two significant products: (1) the Masimo Opioid Halo and (2) the first OTC naloxone nasal spray. Read about how this impacts Resilient's business.
We made some great technical progress and began applying for nondilutive funding
Technical progress and some early testing results
.gif)
